• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage publications (all current information on this profile has been aggregated automatically from publisher and metadata sources).
  • Hagop M Kantarjian, Farhad Ravandi, +22 authors Elias J Jabbour
  • Medicine
  • The Lancet. Oncology
  • 2018
  • BACKGROUND Inotuzumab ozogamicin, an anti-CD22 monoclonal antibody bound to a toxin, calicheamicin, has shown single-agent activity in relapsed or refractory acute lymphoblastic leukaemia. We aimedContinue Reading
  • Elias J Jabbour, Farhad Ravandi, +20 authors Hagop Kantarjian
  • Medicine
  • JAMA oncology
  • 2017 (First Published: 31 August 2017)
  • Importance The outcome of patients with relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL) is poor. Inotuzumab ozogamicin, a CD22 monoclonal antibody bound to calicheamicin, hasContinue Reading
  • Elias J Jabbour, Koji Sasaki, +17 authors Hagop M Kantarjian
  • Medicine
  • Cancer
  • 2018 (First Published: 15 October 2018)
  • BACKGROUND The outcomes of patients with relapsed or refractory (R-R) acute lymphoblastic leukemia (ALL) are poor. Inotuzumab ozogamicin and blinatumomab have single-agent activity in R-R ALL. TheirContinue Reading
  • Koji Sasaki, Elias J Jabbour, +15 authors Hagop M Kantarjian
  • Medicine
  • 2016 (First Published: 2 December 2016)
  • ![Graphic][1] Background: Older patients (pts) with ALL have a worse outcome than younger pts due to poor tolerance of intensive therapy. CD22 expression is present in >90% of pts with B-cell ALL.Continue Reading
  • Koji Sasaki, Hagop M Kantarjian, +18 authors Elias J Jabbour
  • Medicine
  • 2018 (First Published: 29 November 2018)
  • Background: The combination of low intensity therapy with inotuzumab ozogamicin improved survival compared to intensive chemotherapy and to single agent inotuzumab ozogamicin in first salvageContinue Reading
  • Elias J Jabbour, Susan M O'Brien, +10 authors Hagop M Kantarjian
  • Medicine
  • 2015 (First Published: 3 December 2015)
  • ![Graphic][1] Background: Elderly patients with ALL have a significantly poor outcome. This is primarily due to poor tolerance of intensive chemotherapy. Addition of targeted non-myelosuppressiveContinue Reading
  • Koji Sasaki, Hagop M Kantarjian, +13 authors Elias J Jabbour
  • Medicine
  • 2015 (First Published: 3 December 2015)
  • Background: Outcome of patients with R/R ALL is very poor. INO is a CD22 monoclonal antibody bound to a toxin, calecheamicin, and has shown single-agent activity in R/R ALL with a response rate ofContinue Reading
  • Koji Sasaki, Elias J Jabbour, +23 authors Hagop M Kantarjian
  • Medicine
  • 2016 (First Published: 2 December 2016)
  • Background: Outcome of patients with R/R ALL is poor. INO is a CD22 monoclonal antibody bound to a calecheamicin, and has shown single-agent activity in R/R ALL with a response rate of 58% and medianContinue Reading